Tirzepatide Injection
2.5 mg / 0.5 mL
DOCUMENT STATUS Internal website-content and CMS-entry draft. The Raysun carton, autoinjector, and product presentation shown here are concept designs. This document must not be published as public prescription-drug promotion until product approval, local labeling, medical review, and advertising / internet-service compliance have all been confirmed for the target market.
ITEM | PROPOSED WEBSITE ENTRY |
Generic name | Tirzepatide Injection |
Strength | 2.5 mg / 0.5 mL |
Nominal concentration | 5 mg/mL (calculated from strength) |
Dosage form / route | Solution for injection; subcutaneous use |
Concept device | Single-dose prefilled autoinjector |
Concept carton size | 45 × 27 × 170 mm |
Strength identification color | Purple |
1. Recommended Product-Page Copy
Page title: Tirzepatide Injection 2.5 mg / 0.5 mL
Hero statement: A concept initiation strength within a once-weekly tirzepatide treatment pathway.
1.1 Product Overview
This page presents the concept packaging and single-dose prefilled autoinjector for Raysun Tirzepatide Injection 2.5 mg / 0.5 mL. Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. The concept device is labeled to deliver 0.5 mL. Approved indications, formulation, excipients, pack count, shelf life, storage conditions, and instructions for use must be taken only from the final Raysun registration dossier and prescribing information in each target market.
1.2 Position Within the Strength Range
INITIATION STRENGTH (REFERENCE POSITIONING) Based on current U.S. FDA prescribing information, 2.5 mg once weekly is used for treatment initiation and is not a maintenance dose. Reference labeling commonly advances to 5 mg after four weeks. Any Raysun dosing statement must reproduce the finally approved local prescribing information for the target market.
1.3 Strength and Packaging Information
WEBSITE FIELD | RECOMMENDED DISPLAY | RELEASE STATUS |
Active ingredient | Tirzepatide | Scientific information; registration confirmation required |
Strength | 2.5 mg / 0.5 mL | Design input; registration confirmation required |
Nominal concentration | 5 mg/mL | Calculated value; Quality confirmation required |
Delivered volume | 0.5 mL per device | Design input; registration confirmation required |
Presentation | Single-dose prefilled autoinjector | Concept; device and packaging confirmation required |
Proposed pack count | 1 device per carton (concept) | Final registered pack confirmation required |
Carton dimensions | 45 × 27 × 170 mm | Current design input |
1.4 Autoinjector Display Description
The concept pen uses a white medical-grade polymer body with a purple cap, circumferential identification band, and strength label. A medication viewing window is shown on the front, and both the device and carton carry the RAYSUN identity and strength. Locking, unlocking, actuation, end-of-injection feedback, needle protection, and user steps must be established through usability engineering, risk management, container-closure integrity studies, and combination-product verification.
2. Medical and Safety Information (Controlled Content)
CONTROL RULE The following material is a framework for Medical and Regulatory teams preparing a restricted professional page or internal knowledge base. It is not an approved Raysun label. Final web content must be reconciled line by line with the locally approved prescribing information and must not omit or weaken boxed warnings, contraindications, or material risks.
2.1 Administration Framework
TOPIC | CONTROLLED-CONTENT DRAFT |
Frequency | Reference tirzepatide labeling uses once-weekly administration; the approved Raysun frequency controls. |
Route | Subcutaneous injection; reference sites include the abdomen, thigh, or upper arm, with site rotation. |
Dose adjustment | Do not provide individualized adjustment advice. Show only the approved titration and missed-dose instructions. |
Training | Users should receive training from a healthcare professional and the approved Instructions for Use. |
Concomitant therapy | Use with insulin or an insulin secretagogue may increase hypoglycemia risk; use final approved interaction wording. |
2.2 Storage and Distribution Framework
Approved U.S. single-dose tirzepatide products are generally stored refrigerated at 2–8°C, protected from light, and must not be frozen; some approved labels permit limited storage within a specified room-temperature range and duration. The Raysun website must not copy a reference product's room-temperature allowance. Final storage and transport claims must be supported by Raysun stability studies, shipping validation, and the approved local label.
2.3 Important Safety Information Framework
CATEGORY | CONTENT REQUIRING MEDICAL / REGULATORY APPROVAL BEFORE RELEASE |
Boxed warning | Risk of thyroid C-cell tumors and the statement regarding relevance to humans. |
Contraindications | Personal or family history of medullary thyroid carcinoma, MEN 2, and serious hypersensitivity. |
Major risks | Pancreatitis, hypoglycemia, acute kidney injury / volume depletion, severe gastrointestinal reactions, gallbladder disease, and hypersensitivity. |
Additional warnings | Diabetic retinopathy complications, delayed gastric emptying and oral drug absorption, and pulmonary aspiration during anesthesia or deep sedation. |
Special populations | Pregnancy, lactation, pediatric use, and renal / hepatic impairment must match the approved local label. |
Common adverse reactions | Use only events and frequencies from the approved Raysun label; reference-product rates are not Raysun product data. |
3. Website CMS Entry Information
CMS FIELD | RECOMMENDED ENTRY |
Page title | Tirzepatide Injection 2.5 mg / 0.5 mL |
URL slug | tirzepatide-2-5mg-0-5ml |
Meta title | Tirzepatide Injection 2.5 mg / 0.5 mL | Raysun Concept Product |
Meta description | Concept product information for the Raysun Tirzepatide Injection 2.5 mg / 0.5 mL single-dose prefilled autoinjector. Approved indications and use information will be governed by the final local label. |
Product image file | Raysun_Tirzepatide_2.5mg.png |
Image alt text | Raysun Tirzepatide Injection 2.5 mg / 0.5 mL concept carton and purple-coded autoinjector |
Product category | Peptide medicine / Subcutaneous injection / Autoinjector |
Access level | Recommended: internal or restricted HCP access; configure after Legal review |
4. Pre-Publication Completion and Approval Checklist
FUNCTION | FIELDS TO COMPLETE OR CONFIRM | STATUS |
Regulatory | Approval number, countries / regions, indications, prescribing information, and label version | Pending |
Medical | Dose positioning, dosage, contraindications, warnings, adverse reactions, and patient education | Pending |
Quality | Formulation, release specifications, appearance, shelf life, storage, and transportation | Pending |
Packaging / Device | Pack count, pen configuration, container system, IFU, UDI / traceability, and final carton size | Pending |
Legal / Compliance | Rx-advertising status, access controls, ad review, domain credentials, and disclaimers | Pending |
Drug Safety / PV | Adverse-event reporting route, contact details, privacy notice, and escalation process | Pending |
Web Operations | Content version, reviewers, approval date, effective / review date, and takedown process | Pending |
5. Publication and Regulatory Compliance Note
IMPORTANT Prescription-drug website content must be assessed under the law of every target market. In China, the Measures for the Administration of Internet Advertising prohibit prescription-drug advertising on the internet, and the Advertising Law limits prescription-drug advertising to designated medical and pharmaceutical publications. This draft must therefore not be uploaded as a public promotional product page for China. A corporate pipeline page must remain non-promotional, make no efficacy promise, and provide no purchase direction. Restricted professional content still requires confirmation of access controls, internet drug-information qualifications, source attribution, and review requirements. Other markets require separate local assessment.
6. Reference Sources
[1] U.S. FDA: MOUNJARO (tirzepatide) Prescribing Information, 2026 Open source
[2] U.S. FDA: ZEPBOUND (tirzepatide) Prescribing Information, 2026 Open source
[3] China National Healthcare Security Administration: 2025 tirzepatide submission materials Open source
[4] China State Administration for Market Regulation: Measures for the Administration of Internet Advertising Open source
[5] China State Administration for Market Regulation: Advertising Law of the People's Republic of China Open source
[6] China State Administration for Market Regulation: Measures for Internet Drug Information Services Open source
